Satsuma Pharmaceuticals Equity 2024

Satsuma Pharmaceuticals Aktienanalyse

What does Satsuma Pharmaceuticals do?

Satsuma Pharmaceuticals Inc is a young company that was founded in 2016. The company is a biotechnology company specializing in the development and commercialization of medications for the treatment of migraines. Its headquarters are located in South San Francisco, California. The business model of Satsuma Pharmaceuticals is based on the development of medications for the treatment of migraines. The company uses the latest research findings to develop more effective treatment options for patients with migraines. Migraine is one of the most common neurological disorders worldwide. It is estimated that approximately 1 billion people worldwide suffer from this disease, with women being more commonly affected than men due to hormonal differences. Satsuma Pharmaceuticals aims to combat this widespread disease by reducing the severity and frequency of migraine attacks for patients. To achieve its goals, Satsuma Pharmaceuticals has developed a technology platform that enables the development of new medications for the treatment of migraines. This platform is based on the latest developments in medication development and includes various areas such as drug research, preclinical development, clinical development, and approval processes. Satsuma Pharmaceuticals closely collaborates with leading physicians and researchers to develop its medications. The company conducts clinical trials to evaluate the effectiveness and safety of its medications and hopes to soon bring its first products to the market. Currently, Satsuma Pharmaceuticals is focused on the clinical development of a medication called STS101 for the treatment of migraines. This medication is a combination of an already established migraine medication and a new formulation technology. STS101 aims to quickly and effectively treat migraine attacks, thus improving the quality of life for patients with migraines. The company believes that STS101 represents a significant breakthrough in the treatment of migraines. Overall, Satsuma Pharmaceuticals is a promising company that has focused on combating one of the most common neurological disorders in the world. Through close collaboration with leading researchers and physicians, as well as new technology platforms, the company has the potential to make significant advancements in the development of medications for the treatment of migraines and thus improve the lives of millions of people worldwide. Satsuma Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Satsuma Pharmaceuticals's Equity

Satsuma Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Satsuma Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Satsuma Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Satsuma Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Satsuma Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Satsuma Pharmaceuticals stock

What is the equity of Satsuma Pharmaceuticals this year?

Satsuma Pharmaceuticals has equity of 46.82 M USD this year.

What was the equity of Satsuma Pharmaceuticals compared to the previous year?

The equity of Satsuma Pharmaceuticals has increased/decreased by -53.8% decreased compared to the previous year.

What impact does a high equity have on investors of Satsuma Pharmaceuticals?

A high equity is advantageous for investors of Satsuma Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Satsuma Pharmaceuticals?

A low equity can be a risk for investors of Satsuma Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Satsuma Pharmaceuticals affect the company?

An increase in equity of Satsuma Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Satsuma Pharmaceuticals affect the company?

A reduction in equity of Satsuma Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Satsuma Pharmaceuticals?

Some factors that can affect the equity of Satsuma Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Satsuma Pharmaceuticals so important for investors?

The equity of Satsuma Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Satsuma Pharmaceuticals take to change the equity?

To change equity, Satsuma Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Satsuma Pharmaceuticals pay?

Over the past 12 months, Satsuma Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Satsuma Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Satsuma Pharmaceuticals?

The current dividend yield of Satsuma Pharmaceuticals is .

When does Satsuma Pharmaceuticals pay dividends?

Satsuma Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, December, March, April.

How secure is the dividend of Satsuma Pharmaceuticals?

Satsuma Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Satsuma Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Satsuma Pharmaceuticals located?

Satsuma Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Satsuma Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Satsuma Pharmaceuticals from 4/15/2014 amounting to 0.2 USD, you needed to have the stock in your portfolio before the ex-date on 3/28/2014.

When did Satsuma Pharmaceuticals pay the last dividend?

The last dividend was paid out on 4/15/2014.

What was the dividend of Satsuma Pharmaceuticals in the year 2023?

In the year 2023, Satsuma Pharmaceuticals distributed 0 USD as dividends.

In which currency does Satsuma Pharmaceuticals pay out the dividend?

The dividends of Satsuma Pharmaceuticals are distributed in USD.